Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor: EQUIPOTENT TO C34 AND T-20 IN VITRO WITH SUSTAINED ACTIVITY IN SCID-HU THY/LIV MICE
Open Access
- 5 December 2008
- journal article
- Published by Elsevier
- Vol. 283 (49), 34045-34052
- https://doi.org/10.1074/jbc.m805536200
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding AgentAntimicrobial Agents and Chemotherapy, 2008
- Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv MicePLOS ONE, 2007
- Validation of the SCID-hu Thy/Liv Mouse Model with Four Classes of Licensed AntiretroviralsPLOS ONE, 2007
- Electron Tomography of the Contact between T Cells and SIV/HIV-1: Implications for Viral EntryPLoS Pathogens, 2007
- Where Does HIV Live?New England Journal of Medicine, 2004
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtideJournal of the American Academy of Dermatology, 2003
- Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformationJournal of Molecular Biology, 2000
- Potent Inhibition of Replication of Primary HIV Type 1 Isolates in Peripheral Blood Lymphocytes by Negatively Charged Human Serum AlbuminsAIDS Research and Human Retroviruses, 1997
- Maleylated human serum albumin inhibits HIV-1 infection in vitroBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1992
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985